Impact of Bulky & Liposomal Secukinumab on Lymphocytes of Psoriatic Patients, to Determine the Improvement in Bioavailability of Secukinumab Nanolipo
DOI:
https://doi.org/10.54536/ajlsi.v4i1.3268Keywords:
Geno Toxicity, Micronucleus Assay, Oxidative Stress, Psoriasis, SecukinumabAbstract
Psoriasis is an immune-mediated disease affecting the skin and joints. biologic treatments are often used in moderate to severe cases, administered as a monotherapy or in combination with other treatments. Liposomes are versatile and can enhance drug retention, reducing systemic side effects, and are used for therapy and research. This research study aimed to investigate the Geno toxicity of Secukinumab, an ideal biologic treatment for psoriasis (a human IgG1k antibody, anti-IL17A), in bulk and liposome nanoparticles on the lymphocytes of psoriatic patients in comparison with healthy persons. Geno toxicity of Secukinumab in bulk and liposomal form was evaluated and compared by using the Comet and micronucleus assays. From assays, it was demonstrated that Secukinumab in both forms did not exhibit Geno toxicity and reduced DNA damage following the treatment of psoriatic patient lymphocytes and healthy individual’s lymphocytes with Secukinumab bulk and liposomes format. Secukinumab used (2.1 and 2.8 µg/mL) with two different concentrations, and effectively decreased DNA damage induced by H2O2 in both groups to almost the negative control level. Secukinumab bulk and liposome form markedly reduced the H2O2-induced damage and proficiently diminished its adverse effects both in the Comet (p<0.0001) and micronucleus as-says (p<0.01). Overall, Secukinumab in both forms showed anti-genotoxic and protective effects by expressing its potential to reduce DNA damage produced by oxidative stress and it was observed that it would not induce any further damage in the lymphocytes of healthy individuals and patients.
Downloads
References
Bagel, J., Blauvelt, A., Nia, J., Hashim, P., Patekar, M., De Vera, A. (2021). Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). Journal of the European Academy of Dermatology and Venereology, 35(1), 135–142.
Berg, S. H., Balogh, E. A., Ghamrawi, R. I., & Feldman, S. R. (2021). A review of secukinumab in psoriasis treatment. Immunotherapy, 13(3), 201–216.
Bissonnette, R., Luger, T., Thaçi, D., Toth, D., Lacombe, A., Xia, S. (2018). Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). Journal of the European Academy of Dermatology and Venereology, 32(9), 1507–1514.
Bridgewood, C., Wittmann, M., Macleod, T., Watad, A., Newton, D., Bhan, K. (2022). T helper 2 IL-4/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17–type diseases, including seronegative arthritis and enthesitis/enthesopathy, but not to humoral autoimmune diseases. Journal of Investigative Dermatology, 142(10), 2660–2667.
Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., ... & Zhao, L. (2018). Inflammatory responses and inflammation-associated diseases in organs. Oncotarget, 9(6), 7204–7218.
Ciążyńska, M., Olejniczak-Staruch, I., Sobolewska-Sztychny, D., Narbutt, J., Skibińska, M., & Lesiak, A. (2021). Ultraviolet radiation and chronic inflammation—Molecules and mechanisms involved in skin carcinogenesis: A narrative review. Life, 11(4), 326.
Damiani, G., Odorici, G., Pacifico, A., Morrone, A., Conic, R. R., Davidson, T., et al. (2022). Secukinumab loss of efficacy is perfectly counteracted by the introduction of combination therapy (rescue therapy): Data from a multicenter real-life study in a cohort of Italian psoriatic patients that avoided secukinumab switching. Pharmaceuticals, 15(1), 95
Elder, J. T. (Ed.). (2018). Expanded genome-wide association study meta-analysis of psoriasis expands the catalog of common psoriasis-associated variants. Journal of Investigative Dermatology Symposium Proceedings. Elsevier.
Fenech, M., Knasmueller, S., Bolognesi, C., Bonassi, S., Holland, N., Migliore, L., et al. (2016). Molecular mechanisms by which in vivo exposure to exogenous chemical genotoxic agents can lead to micronucleus formation in lymphocytes in vivo and ex vivo in humans. Mutation Research/Reviews in Mutation Research, 770, 12–25.
Fenech, M. (2007). Cytokinesis-block micronucleus cytome assay. Nature Protocols, 2(5), 1084–1104.
Fenech, M. (2009). A lifetime passion for micronucleus cytome assays—reflections from Down Under. Mutation Research/Reviews in Mutation Research, 681(2-3), 111–117.
Griffiths, C. E., & Barker, J. N. (2007). Pathogenesis and clinical features of psoriasis. The Lancet, 370(9583), 263–271.
Kadam, D. P., Suryakar, A. N., Ankush, R. D., Kadam, C. Y., & Deshpande, K. H. (2010). Role of oxidative stress in various stages of psoriasis. Indian Journal of Clinical Biochemistry, 25, 388–392.
Lai, R., Xian, D., Xiong, X., Yang, L., Song, J., & Zhong, J. (2018). Proanthocyanidins: Novel treatment for psoriasis that reduces oxidative stress and modulates Th17 and Treg cells. Redox Report, 23(1), 130–135.
Lin, X., & Huang, T. (2016). Oxidative stress in psoriasis and potential therapeutic use of antioxidants. Free Radical Research, 50(6), 585–595.
Lombardo, D., & Kiselev, M. A. (2022). Methods of liposomes preparation: Formation and control factors of versatile nanocarriers for biomedical and nanomedicine application. Pharmaceutics, 14(3), 543.
Matsuzaki, G., & Umemura, M. (2018). Interleukin‐17 family cytokines in protective immunity against infections: Role of hematopoietic cell‐derived and non‐hematopoietic cell‐derived interleukin‐17s. Microbiology and Immunology, 62(1), 1–13.
Magdolenova, Z., Lorenzo, Y., Collins, A., & Dusinska, M. (2012). Can standard genotoxicity tests be applied to nanoparticles? Journal of Toxicology and Environmental Health, Part A, 75(13-15), 800–806.
Miyagawa, F. (2022). Pathogenesis of paradoxical reactions associated with targeted biologic agents for inflammatory skin diseases. Biomedicines, 10(7), 1485.
Molden, R., Hu, M., Yen, E. S., Saggese, D., Reilly, J., Mattila, J. (Eds.). (2021). Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development. mAbs, 13(1), 1901684.
Najafzadeh, M., & Anderson, D. (2016). The use of isolated peripheral lymphocytes and human whole blood in the comet assay. Comet Assay in Toxicology, 177–191.
Najafzadeh, M., Gueidan, C., Badali, H., Van Den Ende, A. G., Xi, L., & De Hoog, G. (2009). Genetic diversity and species delimitation in the opportunistic genus Fonsecaea. Medical Mycology, 47(1), 17–25.
Nestle, F., Turka, L., & Nickoloff, B. (1994). Characterization of dermal dendritic cells in psoriasis: Autostimulation of T lymphocytes and induction of Th1 type cytokines. The Journal of Clinical Investigation, 94(1), 202–209.
Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022). Liposomes: Structure, composition, types, and clinical applications. Heliyon, 8(2), e08829.
Organisation for Economic Co-operation and Development (OECD). (2010). Test No. 487: In vitro mammalian cell micronucleus test. OECD Publishing.
Rendon, A., & Schäkel, K. (2019). Psoriasis pathogenesis and treatment. International Journal of Molecular Sciences, 20(6), 1475.
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015). Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology, 6, 286.
Schweikert, B., Malmberg, C., Åkerborg, Ö., Kumar, G., Nott, D., Kiri, S. (2020). Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab in the treatment of active psoriatic arthritis with concomitant moderate-to-severe psoriasis in the UK. PharmacoEconomics - Open, 4(4), 635–648.
Stanić, D., Plećaš-Solarović, B., Petrović, J., Bogavac-Stanojević, N., Sopić, M., Kotur-Stevuljević, J., et al. (2016). Hydrogen peroxide-induced oxidative damage in peripheral blood lymphocytes from rats chronically treated with corticosterone: The protective effect of oxytocin treatment. Chemico-Biological Interactions, 256, 134–141.
Tice, R. R., Agurell, E., Anderson, D., Burlinson, B., Hartmann, A., Kobayashi, H., ... & Sasaki, Y. F. (2000). Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environmental and Molecular Mutagenesis, 35(3), 206–221.
Wagener, F. A., Carels, C. E., & Lundvig, D. M. (2013). Targeting the redox balance in inflammatory skin conditions. International Journal of Molecular Sciences, 14(5), 9126–9167.
Yamanaka, K. (2021). Skin disease and comorbidities. MDPI, 11(8), 5754.
Zou, Y., & Meng, Z. (2021). Literature overview of the IL-17 inhibition from psoriasis to COVID-19. Journal of Inflammation Research, 14, 5611–5621.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Gazala Layas, Mohammad Isreb, Nader Ghaderi, Fanila Shahzad, Pouria Akhbari, Diana Anderson, Andrew Wright, Mojgan Najafzadeh
This work is licensed under a Creative Commons Attribution 4.0 International License.
